ELTX

Elicio Therapeutics, Inc. (ELTX) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Elicio Therapeutics is a clinical-stage biotechnology company developing novel immunotherapies for cancer, specifically targeting mKRAS-positive tumors. The company's lead candidate, ELI-002 7P, is currently in a Phase 2 study (AMPLIFY-7P) for pancreatic ductal adenocarcinoma (PDAC). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased slightly by 1% ($0.1 million) to $10.6 million. Research and Development (R&D) expenses declined 13% to $6.8 million, primarily due to patients in the Phase 2 ELI-002 7P study moving from active dosing to follow-up phases. Conversely, General and Administrative (G&A) expenses increased 30% to $3.8 million, driven by increased headcount and professional fees.
• Other Expense: Net other expense increased significantly by 158% to $1.2 million. This was driven by a $1.0 million loss from the change in fair value of warrant liabilities and increased interest expense related to a new promissory note.
• Liquidity: Cash and cash equivalents decreased by $3.6 million during the quarter. The company raised approximately $8.0 million in net proceeds through At-The-Market (ATM) offerings.
• Debt Structure: The company converted a $20.0 million convertible note into equity in March 2025. In June 2025, it issued a new $10.0 million Senior Secured Promissory Note, which appears on the balance sheet as long-term debt.

Guidance, Outlook, and Risks

• Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management estimates current cash resources will fund operations into the fourth quarter of 2026. Additional financing is required to continue development.
• Clinical Outlook: The Independent Data Monitoring Committee (IDMC) recommended continuing the Phase 2 AMPLIFY-7P study without modifications following an interim review in August 2025. The final disease-free survival analysis is anticipated in mid-2026.
• Financing Activities: The company terminated its 2024 ATM program in March 2026 and initiated a new 2026 ATM program with a capacity of $100 million. Subsequent to the quarter end (through May 8, 2026), the company raised an additional $5.0 million under this new program.
• Risks: Key risks include the inability to secure additional capital, delays in clinical trials, failure to demonstrate efficacy, and reliance on third-party manufacturers. The company also faces potential dilution from future equity offerings.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "fourth quarter 2026" cash runway estimate given the high burn rate (~$11.6M/quarter operating cash use).
• Debt Covenants: Review the terms of the $10.0 million Senior Secured Promissory Note (interest rate capped at 12.5%, secured by substantially all assets) for potential covenants or prepayment penalties.
• Warrant Liability Volatility: Monitor the fair value of liability-classified warrants, as fluctuations significantly impact net loss (e.g., $1.0M loss in Q1 2026).
• Clinical Milestones: Confirm the timeline for the final analysis of the AMPLIFY-7P Phase 2 study, as this is the primary catalyst for future valuation.
• Dilution: Assess the impact of ongoing ATM sales and outstanding warrants (over 6 million shares underlying warrants) on existing shareholder equity.